Marrow morphology of chronic myelogenous leukemia in patients treated with imatinib mesylate (Gleevac, Sti-571): Correlation with cytogenetic response

被引：0
|
作者：
Racke, F
Allan, RW
Miller, C
Weir, EG
机构：
[1] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[2] St Agnes Hosp, Baltimore, MD USA
来源：
MODERN PATHOLOGY | 2005年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1148
引用
收藏
页码：248A / 248A
页数：1
相关论文
共 50 条
  • [1] Marrow morphology of chronic myelogenous leukemia in patients treated with imatinib mesylate (Gleevac, Sti-571): Correlation with cytogenetic response
    Racke, F
    Allan, RW
    Miller, C
    Weir, EG
    LABORATORY INVESTIGATION, 2005, 85 : 248A - 248A
  • [2] Pharmacogenetic analysis of cytogenetic response in chronic myelogenous leukemia patients treated with imatinib (Glivec®/Gleevec™, STI571).
    Malinowski, RH
    Dressman, M
    McLean, LA
    Gathmann, I
    Capdeville, R
    BLOOD, 2002, 100 (11) : 547A - 547A
  • [3] The clinical course of thrombocytopenia in patients treated with STI-571 (IMATINIB) for accelerated phase chronic myelogenous leukemia.
    van Deventer, HW
    Hall, MD
    Mitchell, BS
    Hogan, CM
    Lehman, MJ
    Bhagat, RK
    Berkowitz, LR
    Dunphy, CH
    Orlowski, RZ
    Stinchcombe, TE
    Smith, JS
    Powderly, JD
    Rao, KW
    Koehler, JA
    Nashed, A
    Shea, TC
    BLOOD, 2001, 98 (11) : 139A - 139A
  • [4] An unusual case of central nervous system chloroma in a patient with chronic myelogenous leukemia responding to imatinib mesylate (STI-571).
    Mashru, SH
    Loscalzo, JJ
    BLOOD, 2002, 100 (11) : 322B - 322B
  • [5] Stem cell collection in chronic myeloid leukemia patients with cytogenetic response to imatinib mesylate (STI 571, gleevec)
    Hardan, I
    Lennard, A
    Nagler, A
    Shimoni, A
    Sareli, R
    Boque, C
    Canzio, M
    Olavarria, E
    Niederwieser, D
    BONE MARROW TRANSPLANTATION, 2003, 31 : S62 - S62
  • [6] Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571)
    Dressman, MA
    Malinowski, R
    McLean, LA
    Gathmann, I
    Capdeville, R
    Hensley, M
    Polymeropoulos, MH
    CLINICAL CANCER RESEARCH, 2004, 10 (07) : 2265 - 2271
  • [7] Effects of the tyrosine kinase inhibitor Imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia
    Thiele, J
    Kvasnicka, HM
    Schmitt-Graeff, A
    Kriener, S
    Engels, K
    Staib, P
    Griesshammer, M
    Waller, CF
    Ottmann, OG
    Hansmann, M
    HISTOLOGY AND HISTOPATHOLOGY, 2004, 19 (04) : 1277 - 1288
  • [8] Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia
    Ebos, JML
    Tran, J
    Master, Z
    Dumont, D
    Melo, JV
    Buchdunger, E
    Kerbel, RS
    MOLECULAR CANCER RESEARCH, 2002, 1 (02) : 89 - 95
  • [9] Skin reactions to imatinib mesylate (STI-571) in patients with chronic myeloid leukemia (CML): Clinical features and histopathology.
    Stone, R
    Galinsky, I
    Haynes, H
    Soiffer, R
    Alyea, E
    Neuberg, D
    Tawa, M
    Antin, J
    Resta, D
    Granter, S
    DeAngelo, D
    BLOOD, 2001, 98 (11) : 141A - 141A
  • [10] Lack of cytogenetic response is an adverse prognostic factor for relapse of chronic phase CML patients treated with imatinib mesylate (STI571).
    O'Dwyer, M
    Mauro, MJ
    Blasdel, C
    Farnsworth, M
    Kurilik, G
    Fong, D
    Hsieh, YC
    Mori, M
    Capdeville, R
    Druker, BJ
    BLOOD, 2001, 98 (11) : 137A - 138A
12345